Video

ecancer's extensive video archive features interviews, panel discussions and conference coverage on almost every topic in oncology.

CURB phase II trial: Tumour burden predicts survival after SBRT in NSCLC oligoprogression

Dr Matthew McMillan - Memorial Sloan-Kettering Cancer Center, New York, USA
CURB phase II trial: Tumour burden predicts survival after SBRT in NSCLC oligoprogression ( Dr Matthew McMillan - Memorial Sloan-Kettering Cancer Center, New York, USA )
22 Sep 2025

WCLC 2025: Latest in EGFR positive NSCLC

Prof Enriqueta Felip, Dr Antonio Passaro, Dr Alex Spira and Prof Ignacio Gil-Bazo
WCLC 2025: Latest in EGFR positive NSCLC ( Prof Enriqueta Felip, Dr Antonio Passaro, Dr Alex Spira and Prof Ignacio Gil-Bazo )
9 Sep 2025

Dose escalation of RG6344 demonstrates safety and promising activity in BRAF V600E solid tumours

Dr Maria Vieito - Vall d'Hebron Institute of Oncology, Barcelona, Spain
Dose escalation of RG6344 demonstrates safety and promising activity in BRAF V600E solid tumours ( Dr Maria Vieito - Vall d'Hebron Institute of Oncology, Barcelona, Spain )
1 Sep 2025

Treatment management of favourable risk and very favourable risk patients

Dr Guillermo de Velasco and Dr Marco Maruzzo
Treatment management of favourable risk and very favourable risk patients ( Dr Guillermo de Velasco and Dr Marco Maruzzo )
1 Sep 2025

Phase I/II trial shows promising activity of invikafusp alfa in PD-1–resistant GI cancers

Dr Elena Élez - Vall d'Hebron Institute of Oncology, Barcelona, Spain
Phase I/II trial shows promising activity of invikafusp alfa in PD-1–resistant GI cancers ( Dr Elena Élez - Vall d'Hebron Institute of Oncology, Barcelona, Spain )
18 Aug 2025

Nivolumab plus ipilimumab improves survival results in MSI-H/dMMR metastatic colorectal cancer

Dr Elena Élez - Vall d'Hebron Institute of Oncology, Barcelona, Spain
Nivolumab plus ipilimumab improves survival results in MSI-H/dMMR metastatic colorectal cancer ( Dr Elena Élez - Vall d'Hebron Institute of Oncology, Barcelona, Spain )
18 Aug 2025

Key insights from head and neck research at ASCO 2025

Dr Barbara Burtness - Yale School of Medicine, New Haven, USA
Key insights from head and neck research at ASCO 2025 ( Dr Barbara Burtness - Yale School of Medicine, New Haven, USA )
8 Aug 2025

ASCO 2025: Developments in the treatment of soft tissue sarcoma

Dr Atif Hussein - Memorial Cancer Institute, Miami, USA
ASCO 2025: Developments in the treatment of soft tissue sarcoma ( Dr Atif Hussein - Memorial Cancer Institute, Miami, USA )
31 Jul 2025

Transforming cancer care in India: The Access Cancer Care Initiative

Prof Richard Sullivan, Dr Ishu Kataria and Dr Arunah Chandran
Transforming cancer care in India: The Access Cancer Care Initiative ( Prof Richard Sullivan, Dr Ishu Kataria and Dr Arunah Chandran )
17 Jul 2025

Lurbinectedin plus atezolizumab improves PFS and OS in ES-SCLC first-line maintenance

Dr Luis Paz-Ares - Hospital Universitario 12 de Octubre, Madrid, Spain
Lurbinectedin plus atezolizumab improves PFS and OS in ES-SCLC first-line maintenance ( Dr Luis Paz-Ares - Hospital Universitario 12 de Octubre, Madrid, Spain )
17 Jul 2025

Encorafenib, cetuximab plus chemotherapy yields good response in BRAF V600E mCRC

Dr Scott Kopetz - MD Anderson Cancer Center, Houston, Texas
Encorafenib, cetuximab plus chemotherapy yields good response in BRAF V600E mCRC ( Dr Scott Kopetz - MD Anderson Cancer Center, Houston, Texas )
17 Jul 2025

Durvalumab and tremelimumab show manageable safety in poor-prognosis HCC

Prof Stephen Chan - The Chinese University of Hong Kong, Ma Liu Shui, Hong Kong
Durvalumab and tremelimumab show manageable safety in poor-prognosis HCC ( Prof Stephen Chan - The Chinese University of Hong Kong, Ma Liu Shui, Hong Kong )
11 Jul 2025